Christoph West­phal and the crew at No­var­tis-backed TScan aren't wait­ing to take their pre­clin­i­cal TCR pitch to Nas­daq

Just 3 months ago, TScan CEO David South­well told End­points News’ Nicole De­Feud­is that it was like­ly the on­col­o­gy start­up would go pub­lic at some point, but just how soon af­ter the $100 mil­lion crossover round they were re­port­ing at the time hadn’t been de­cid­ed.

Turns out, they were able to file con­fi­den­tial­ly 53 days af­ter the crossover re­veal, hus­tling ahead to catch the biggest fi­nanc­ing wave in biotech his­to­ry, as just about every stripe of biotech looks ap­pe­tiz­ing to in­vestors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER